文献速递肝胆胰外科胃肠外科

肝移植与ALPPS治疗结直肠癌肝转移的熵平衡回顾性分析

Liver Transplantation Versus ALPPS for Colorectal Liver Metastases: An Entropy Balanced Retrospective Analysis.
PubMed 文献 · Ann Surg · 2025-08-08

该回顾性研究比较肝移植(LT)与ALPPS治疗结直肠癌肝转移(CRLM)的生存结局,纳入46例ALPPS和54例LT患者,熵平衡后两组死亡风险无显著差异(HR=1.40,P=0.398),但失败ALPPS中位OS显著低于LT(31.1个月 vs 未达到,P=0.043),符合SECA-II标准者LT组OS显著更高(P=0.022)。

要点

  • 熵平衡后ALPPS与LT死亡风险无显著差异(HR=1.40,95%CI 0.63-3.09,P=0.398)。
  • 失败ALPPS中位OS 31.1个月,显著低于LT(P=0.043)。
  • 符合SECA-II标准者LT组中位OS未达到,显著高于ALPPS的76个月(P=0.022)。

核心结论

  • 在不采用当前严格选择标准的情况下,肝移植相比ALPPS未提供显著生存获益。
  • 两种策略的最终选择似乎取决于能否完成二期手术以及患者是否符合最新移植标准。

研究设计与样本

  • 回顾性分析,纳入14个中心2012年9月至2022年9月连续接受ALPPS的121例CRLM患者,筛选46例符合标准者。
  • 采用熵平衡法消除混杂偏倚。

主要发现

  • ALPPS组中位OS为76个月(95%CI 28.9-123),LT组为72.7个月(95%CI 43.4-102)。
  • 熵平衡后ALPPS相关死亡风险高于LT(HR=1.40,95%CI 0.63-3.09),但无统计学差异(P=0.398)。
  • 失败ALPPS中位OS为31.1个月(95%CI 0-73.3),显著低于LT组(P=0.043)。
  • 按SECA-II标准筛选后,LT组中位OS未达到,显著高于ALPPS组的76个月(95%CI 21-130)(P=0.022)。

临床怎么用

  • 临床选择LT或ALPPS时需评估二期手术完成的可能性及患者是否符合最新移植标准。
  • 失败ALPPS患者生存预后较差,应谨慎筛选适合ALPPS的病例。

局限性

  • 回顾性研究设计,ALPPS组来自多中心而LT组来自单中心。
  • 样本量有限(ALPPS 46例,LT 54例)。
  • 研究时间跨度不同(ALPPS 2012-2022,LT 2006-2019)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The primary endpoint of this study was to compare liver transplantation (LT) with Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) in the treatment of colorectal liver metastases (CRLM). BACKGROUND: ALPPS is usually performed for borderline CRLM cases and published oncological outcomes appear to be inferior to those obtained after LT. METHODS: All consecutive patients undergoing ALPPS for CRLM across 14 centers between September 2012 and September 2022 were considered. The selected ALPPS patients were compared with patients receiving LT from November 2006 to June 2019 performed at a single institution. Entropy balancing was applied to eliminate all confounding bias simulating what would have happened if ALPPS patients had been transplanted. RESULTS: During the study period, 121 consecutive patients were submitted to ALPPS and 46 were enrolled by fulfilling the inclusion criteria. These 46 cases were compared with 54 patients submitted to LT. Median OS after ALPPS was 76 months (95% CI: 28.9-123) compared with 72.7 months in patients who underwent LT (95% CI: 43.4-102 months). After reweighting, the risk of death related to ALPPS was higher when compared with LT (HR=1.40, 95% CI: 0.63-3.09) but no significant differences were found between the 2 groups ( P =0.398). When splitting the ALPPS cohort into completed and failed procedures, the median OS in failed ALPPS (31.1 months, 95% CI: 0-73.3 months) was significantly lower than that of patients submitted to LT ( P =0.043). When ALPPS patients were further selected based on SECA-II criteria, the median OS was significantly ( P =0.022) higher in the LT group (not reached) compared with ALPPS (76 months, 95% CI: 21-130 months). CONCLUSIONS: LT without current stringent selection criteria did not provide a significant survival benefit compared with ALPPS. The final choice between these 2 strategies seems to depend on the possibility of completing stage 2 and whether the patient meets the most updated transplant criteria.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Serenari M, Lanari J, Dueland S, et al. Liver Transplantation Versus ALPPS for Colorectal Liver Metastases: An Entropy Balanced Retrospective Analysis. Ann Surg. 2025. PMID: 40778636. doi:10.1097/SLA.0000000000006899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。